 IRVINE, Calif., Aug. 30, 2021 GLOBE NEWSWIRE -- Biomerica Inc. NASDAQ: BMRA today announced it expects final patient enrollment in its endpoint clinical trial for its InFoods diagnostic-guided therapy DGT, designed to alleviate Irritable Bowel Syndrome IBS symptoms. The clinical trial is being conducted by Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist hospital and the University of Michigan as primary enrollment centers for this study. 